Coherus BioSciences (NASDAQ:CHRS) Research Coverage Started at Robert W. Baird
Robert W. Baird began coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research note published on Friday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $11.00 price target on the biotechnology company’s stock. CHRS has been the subject of a number of other research reports. Truist Financial reaffirmed […]
More Stories
Synovus Financial Corp. (NYSE:SNV) Sees Significant Decline in Short Interest
Synovus Financial Corp. (NYSE:SNV – Get Free Report) was the recipient of a significant drop in short interest during the...
Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Declines By 23.4%
P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) was the recipient of a large drop in short interest in...
Applied Materials (NASDAQ:AMAT) Announces Earnings Results, Beats Expectations By $0.13 EPS
Applied Materials (NASDAQ:AMAT – Get Free Report) issued its earnings results on Thursday. The manufacturing equipment provider reported $2.32 earnings...
Prenetics Global Limited (NASDAQ:PRE) Short Interest Update
Prenetics Global Limited (NASDAQ:PRE – Get Free Report) was the recipient of a large growth in short interest during the...
Short Interest in Option Care Health, Inc. (NASDAQ:OPCH) Drops By 24.7%
Option Care Health, Inc. (NASDAQ:OPCH – Get Free Report) saw a significant decrease in short interest in the month of...
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI) Sees Large Increase in Short Interest
Global X NASDAQ 100 Risk Managed Income ETF (NASDAQ:QRMI – Get Free Report) was the recipient of a large increase...